Kura肿瘤学 KURA 深 沪
已收盘 10-31 16:00:00 美东时间
10.27
-0.170
-1.63%
华盛通- 最 高10.62
- 今 开10.48
- 成交量 167.00万股
- 最 低 10.00
- 昨 收 10.44
- 总市值 8.91亿
- 52周最高 19.7283
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 5.41
- 委 比 -37.80%
- 总股本 8679.72万
- 历史最高 43.00
- 量 比 0.67
- 振 幅 5.94%
- 历史最低 2.50
- 每 手 1
- 风险率 2.75%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Kura Oncology Receives $30M Milestone Payment
The latest announcement is out from Kura Oncology ( ($KURA) ). On October 24, 2...
10-24 19:43
Kura Oncology Receives $30 Million Development Milestone Payment in Ziftomenib AML Program with Kyowa Kirin
Kura Oncology received a $30 million milestone payment from Kyowa Kirin upon dosing the first patient in the KOMET-017 Phase 3 trials of ziftomenib, an oral menin inhibitor for acute myeloid leukemia (AML). The KOMET-017 trials evaluate ziftomenib combined with both intensive and non-intensive chemotherapy in newly diagnosed NPM1-mutated or KMT2A-rearranged AML patients. Kura highlights that this is the only menin inhibitor program pursuing regis...
10-24 11:02
美股大行评级 | 潜在涨幅344.44%！Rani Therapeutics获Maxim Group升目标价至10美元，维持"买入"评级
今日重点评级关注：Maxim Group：维持Rani Therapeutics Hldgs"买入"评级，目标价从5美元升至10美元；韦德布什：维持Corbus Pharmaceuticals"跑赢大市"评级，目标价从31美元升至38美元
10-21 18:13
Kura Oncology Announces Preliminary Data from Its Farnesyl Transferase Inhibitor (FTI) Programs at the 2025 European Society for Medical Oncology (ESMO) Congress
Kura Oncology announced new preliminary data from its FTI programs, darlifarnib and tipifarnib, at the 2025 ESMO Congress. Darlifarnib showed promising antitumor activity in HRAS-mutant solid tumors and, when combined with cabozantinib in renal cell carcinoma, achieved a 50% objective response rate and 80% disease control rate. Tipifarnib combined with alpelisib demonstrated robust activity in PIK3CA-altered head and neck cancer. The company high...
10-18 07:23
Kura Oncology Expands Inducement Option Plan Shares
An announcement from Kura Oncology ( ($KURA) ) is now available. On October 15,...
10-17 04:29
美股大行评级 | 潜在涨幅超31%！摩根大通维持通用汽车"超配"评级，目标价从60美元升至80美元
今日重点评级关注：Maxim Group：上调Adial Pharmaceuticals评级至"买入"，目标价1.5美元；BTIG：维持Climb Bio"买入"评级，目标价从7美元升至8美元
10-01 20:13
Kura Oncology and Kyowa Kirin Launch Clinical Trial Evaluating Dual Inhibition of NPM1 and FLT3 Mutations in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)
Kura Oncology and Kyowa Kirin have initiated the first patient dosing in a cohort of the KOMET-007 clinical trial, evaluating ziftomenib, an investigational menin inhibitor, in combination with cytarabine and daunorubicin, along with quizartinib, for patients with newly diagnosed FLT3/NPM1 co-mutated acute myeloid leukemia (AML). Despite advances in FLT3 inhibitors, patients with FLT3/NPM1 co-mutations face high relapse rates and limited treatmen...
10-01 11:01
Kura Oncology and Kyowa Kirin Announce First Patient Dosed in Pivotal Phase 3 KOMET-017 Trial of Ziftomenib for Frontline Acute Myeloid Leukemia (AML)
Kura Oncology and Kyowa Kirin announced the initiation of the KOMET-017 clinical trial to evaluate ziftomenib, a menin inhibitor, in combination with intensive and non-intensive regimens for newly diagnosed <em>NPM1</em>-mutated or <em>KMT2A</em>-rearranged acute myeloid leukemia (AML). The trial comprises two Phase 3 studies with dual-primary endpoints: intensive chemotherapy trial assessing MRD-negative complete response (CR) and event-free sur...
09-29 20:01
Kura Oncology Announces The Journal Of Clinical Oncology Published The Full Results From The Pivotal KOMET-001 Clinical Trial Evaluating Ziftomenib; KOMET-001 In R/r Npm1-m AML Met Its Primary Endpoint With Ziftomenib Monotherapy Demonstrating Significant Clinical Benefit And Deep Responses
SAN DIEGO and TOKYO, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ: KURA) and Kyowa Kirin Co., Ltd.
09-26 05:25
Kura Oncology and Kyowa Kirin Announce Publication of Pivotal Ziftomenib Data in Relapsed/Refractory NPM1-Mutated AML in the Journal of Clinical Oncology
KOMET-001 trial demonstrates significant clinical benefit of ziftomenib in relapsed/refractory NPM1-m AML, meeting primary endpoint with 22% complete remission rate. The drug shows consistent activity across subgroups, favorable safety profile, and no significant QTc prolongation or myelosuppression. FDA Priority Review with PDUFA date set for November 30, 2025. Currently, no approved therapy targets NPM1-m AML.
09-25 21:18
